Monro Inc (MNRO) Optionen

Merry Christmas!!!! HMBL will bring us prosperity in 25 and beyond ❤️

1. Developing Deramiocel (Cap-1002) to treat cardiomyopathy in Duchene Muscular Dystrophy (DMD)
2. Cardiomyopathy is much larger than DMD. Beckers next. Then at least half a dozen off-label uses.
3. Expect FDA approval in DMD in 2H 2025.
4. And Cedar-Sinai has a couple more we

RE: gitreal
How about re-name to get real, we all know everyone associated with Sidney Resources, names, eMail, address, etc.
but we don't know anything about non-transparent gitreal, why do you suppose? Merry Christmas to all.

Many thanks DMC8 for your links and posts this past year. This particular one sums up Capt Beer’s mantra of “It’s the EPA”, yet again!
It certainly doesn’t hurt for this info to be published Christmas Day in China

So you say . Other side says the same thing .
But you proclaim yourself to be superior . 
Got it . We are just supposed to believe you over everyone else ... just because . 
So you still haven't "honestly " answered the question I asked you 

MERRY CHRISTMAS to everyone


🎅

I agree, at this point, we might as well keep pushing.

Why District Court Decisions Are Often Appealed in Patent Cases
- Patent cases are complex and require interpretation of intricate technical details and legal principles, which district courts may not always get right.

holyshit were #3 wooooo hooooo!!!! maybe NEXT YEAR????? BLHA HA AH HAH AH AH AHAH A AHA HA HAHAHAHA HA AH HAH AH Ahttps://www.thelion.com/

This seems to NEVER END.

I SWEAR...it's forever

😂

Because 99.9% of the trades are done electronically and MM's are the ones that are required to report, little enforcement is needed.
Fails to deliver are electronically-trackable, too. If there were significant fails-to-deliver, then there possibly would be concerns about naked shorting (the

I don't think he said that. He did make a comment once that news would be out by the first of November back last summer but that time came and passed.
Mean while, Humble does his thing of suppressing negative comments. A sure sign that the company wants to get some buying from the uninformed.

I think I should start an investment newsletter featuring companies with accepted MAA's.
I know they don't all go on to become commercial successes and there would be plenty of BP drugs in there too, but the smaller biotech's would be wonderful "story stocks" for my readers.

*****hhse 2024 year review******

1) Eric lied repeatedly in the blog 

2) Eric lied again and again and again 

3) Eric went to Cannes with NOTHING to show for it as well as the last few years 

A true theorySLUT paid to post theorySHIT on multiple massage boards..

KARMA in not a theory, Its a selftrap for good...

Nah only insiders loaded at those cheap prices is why they dropped the fake r/s announcement to spook potential frontloaders when it was trading at 0001/0003

Merry Christmas and a Happy Holiday Season to all.

May 2025 be better then 2024 for SNPW

https://i.pinimg.com/originals/34/bf/11/34bf11ebbc032fe5ace99600810064f4.gif

Merry Christmas to you too. 

Amazon "might" 

lol 

Eric PARKINSON words 

Stick to dress up time 👗 

@tbonaces80 @Princess17
What do you two think about this?
150 million pp says massively misunderstood story? 140mn historical volume too...

Damn, you got a hell a lot of these Paid Ihub accounts. Did you get a discount deal? This is the only social media platform that gets retails attention on this Sht ticker so i guess it is money well spent.

No paid pumpers? Go check the expenses on NWBO, they have several paid pro

Admittedly there could be a slight bias in that most applicants apply to FDA first which may mean if rejected less likely to then apply to EMA.

Yes, but ultimately it is just supply/demand. 

after the supreme court ruled --- misinterpreting the law --- and the 2019 retention of earnings --- the only outcome was recap and release --- and i had to quit my job w-2 to roll my 401k into this as well as then started doing contract work to buy more pre-tax--- working harder 2021-present than e